Xenetic Biosciences (NASDAQ:XBIO) Trading Down 8.7%

Xenetic Biosciences Inc (NASDAQ:XBIO)’s share price was down 8.7% during mid-day trading on Wednesday . The company traded as low as $3.74 and last traded at $3.74. Approximately 1,113 shares changed hands during mid-day trading, a decline of 79% from the average daily volume of 5,331 shares. The stock had previously closed at $4.10.

Xenetic Biosciences Trading Down 8.7 %

The firm’s fifty day simple moving average is $3.94 and its 200 day simple moving average is $3.88. The company has a market cap of $5.77 million, a price-to-earnings ratio of -1.28 and a beta of 2.28.

Xenetic Biosciences (NASDAQ:XBIO) last issued its earnings results on Thursday, May 9th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.01. The firm had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.65 million. Xenetic Biosciences had a negative net margin of 182.99% and a negative return on equity of 43.40%. As a group, sell-side analysts expect that Xenetic Biosciences Inc will post -0.96 EPS for the current year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.